| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.82B | 1.83B | 1.83B | 1.54B | 1.48B | 1.07B |
| Gross Profit | 468.01M | 487.39M | 501.95M | 414.45M | 471.26M | 284.58M |
| EBITDA | 140.81M | 160.68M | 53.50M | 237.57M | 219.79M | -97.78M |
| Net Income | -143.30M | -203.70M | -194.21M | 15.29M | 22.01M | -281.04M |
Balance Sheet | ||||||
| Total Assets | 4.10B | 4.13B | 4.50B | 4.75B | 4.73B | 4.58B |
| Cash, Cash Equivalents and Short-Term Investments | 1.38B | 1.40B | 1.20B | 1.35B | 1.89B | 1.82B |
| Total Debt | 262.47M | 357.62M | 456.94M | 475.02M | 117.97M | 139.88M |
| Total Liabilities | 666.65M | 746.56M | 881.82M | 896.09M | 504.94M | 456.51M |
| Stockholders Equity | 3.01B | 2.98B | 3.24B | 3.49B | 3.86B | 3.81B |
Cash Flow | ||||||
| Free Cash Flow | 172.04M | 206.11M | 229.79M | -5.46M | 151.00M | 3.75M |
| Operating Cash Flow | 213.08M | 244.83M | 247.53M | 31.73M | 170.95M | 39.05M |
| Investing Cash Flow | 291.15M | 164.29M | -20.95M | 587.77M | -261.67M | -742.86M |
| Financing Cash Flow | -182.29M | -235.72M | -151.07M | -518.45M | -90.80M | -93.68M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
71 Outperform | HK$601.91M | 7.29 | 5.33% | 9.14% | 0.47% | 50.46% | |
66 Neutral | HK$1.57B | 5.42 | 20.47% | 4.37% | -3.56% | -17.45% | |
56 Neutral | HK$801.53M | 5.51 | 30.40% | ― | 2.30% | ― | |
52 Neutral | HK$1.66B | -11.56 | -4.66% | 0.49% | -0.55% | 45.36% | |
52 Neutral | HK$1.03B | 39.67 | 1.27% | ― | -4.30% | 13.83% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | HK$1.23B | -9.93 | -3.59% | 2.02% | -4.09% | -1242.31% |
Town Health International Medical Group Limited has updated the terms of reference for its nomination committee, effective 1 January 2026, to reinforce governance over board appointments and composition. The revised framework formalises the committee’s responsibility for fair and transparent director nominations, requires a majority of independent non-executive directors and at least one member of a different gender on the committee, and empowers it to review board structure, assess director independence, oversee succession planning for key leadership roles, and support regular board performance evaluations, thereby strengthening the company’s corporate governance practices and board oversight.
The most recent analyst rating on (HK:3886) stock is a Hold with a HK$0.50 price target. To see the full list of analyst forecasts on Town Health International Medical Group Ltd. stock, see the HK:3886 Stock Forecast page.